Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gelofusine + ringer lactate is a fluid resuscitation combination used in a clinical trial conducted by the Università degli Studi di Ferrara. The regimen consists of a 1:2 ratio of Gelofusine (a 4% succinylated gelatin colloid solution) and Ringer's Lactate (a balanced crystalloid solution). This combination is designed for intravascular volume expansion and maintenance of hemodynamic stability in patients undergoing major elective surgeries, such as abdominal, thoracic, or vascular procedures. The study specifically investigated how this colloid-crystalloid mix affects respiratory mechanics and oxygenation compared to crystalloid therapy alone, aiming to mitigate the potential negative impacts of large fluid volumes on lung parenchyma. Gelofusine acts as a plasma volume expander by increasing oncotic pressure, while Ringer's Lactate provides essential electrolytes and extracellular fluid replacement.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on gelofusine + ringer lactate.